

## Department of Planning and Budget

### 2023 Fiscal Impact Statement

**1. Bill Number:** SB948

<b>House of Origin</b>	<input type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
<b>Second House</b>	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input checked="" type="checkbox"/> Enrolled

**2. Patron:** Suetterlein

**3. Committee:** Passed both Houses.

**4. Title:** Pharmacist scope of practice; initiation of treatment for certain diseases and conditions.

**5. Summary:** Allows pharmacists to initiate treatment with, dispense, or administer controlled substances or devices for treatment of Group A Streptococcus infection, influenza virus infection, and urinary tract infection to persons 18 years of age or older or persons otherwise authorize to consent with whom the pharmacist has a bona fide pharmacist-patient relationship in accordance with regulations set forth by the Board of Pharmacy. The bill directs the Board of Pharmacy to adopt a statewide protocol for the initiation of treatment with and dispensing and administering of drugs and devices by pharmacists in accordance with the provisions of the bill by November 1, 2023. The bill requires that such protocol be developed by a work group consisting of representatives from the Board of Pharmacy, Board of Medicine, and Department of Health, with an equal number of members who are representatives of the Board of Pharmacy and Board of Medicine.

**6. Budget Amendment Necessary:** No.

**7. Fiscal Impact Estimates:** Minimal.

**8. Fiscal Implications:** Any cost for the Department of Health Professions to adopt regulations can be handled within existing resources. This legislation would not have a fiscal impact on the Virginia Department of Health.

**9. Specific Agency or Political Subdivisions Affected:** None.

**10. Technical Amendment Necessary:** No.

**11. Other Comments:** None.